Effect of Autoimmune Cell Therapy on Immune Cell Content in Patients with COPD: A Randomized Controlled Trial.

Wen Li,Guanhong Li,Yuqiong Zheng,Wei Zhou,Hui Wang

doi:10.1155/2022/8361665

Wen Li, Guanhong Li + Show 3 more

Open Access

https://doi.org/10.1155/2022/8361665

Copy DOI

Abstract

Objective To explore the effect of autoimmune cell therapy on immune cells in patients with chronic obstructive pulmonary disease (COPD) and to provide a reference for clinical treatment of COPD. Methods Sixty patients with stable COPD were randomly divided into control group and treatment group (n = 30). The control group was given conventional treatment, and the treatment group was given one autoimmune cell therapy on the basis of conventional treatment. The serum levels of CD3+ T cells, CD4+ T cells, CD8+ cells, B cells, and NK cells in the peripheral blood were detected by flow cytometry. Possible adverse reactions were detected at any time during treatment. Results There were no significant differences in the contents of CD3+ T cells, CD4+ T cells, CD8+ cells, B cells, and NK cells in the serum of the control group (P > 0.05). Compared with before treatment, the contents of CD3+ T cells, CD4+ T cells, CD8+ cells, B cells, and NK cells in the serum of the treatment group were significantly increased (P < 0.05). The ratio of CD4 + /CD8+ T cells in both control and treatment groups did not change significantly during treatment (P > 0.05). There were no significant differences in serum CD3+ T cells, CD4+ T cells, CD8+ cells, B cells, and NK cells in the treatment group at 30 days and 90 days after treatment (P > 0.05), but they were significantly higher than those in the control group (P < 0.05). Conclusion Autoimmune cell therapy can significantly increase the level of immune cells in the body and can be maintained for a long period of time, which has certain clinical benefits for recurrent respiratory tract infections and acute exacerbation in patients with COPD.

Highlights

Chronic obstructive pulmonary disease (COPD) is a common chronic disease of respiratory system, with high morbidity, disability, and mortality [1]
There was no loss during follow-up in the control group, while 1 patient with acute exacerbation within 3 months after the start of the study was excluded from the treatment group
There was no significant difference between the two groups in gender, age, height, weight, BMI, smoking history, diabetes mellitus, hypertension, and Percentage of peripheral blood CD8+ (%)

Summary

Introduction

Chronic obstructive pulmonary disease (COPD) is a common chronic disease of respiratory system, with high morbidity, disability, and mortality [1]. Especially cigarette smoke, is the most common cause of COPD These patients exhibit a progressive airflow obstruction provoked by small airway fibrosis, alveolar wall destruction (emphysema), and chronic inflammation [3]. Inhaled corticosteroids (ICSs) are used extensively in the treatment of asthma and COPD due to their broad anti-inflammatory effects. They improve lung function, symptoms, and quality of life and reduce exacerbations in both conditions but do not alter the progression of disease. They decrease mortality in asthma but not COPD. Longterm treatment with ICSs is recommended by the GOLD guidelines for patients with an FEV1 < 50% predicted and/ or frequent exacerbations and whose symptoms are not adequately controlled on long-acting bronchodilators, long-term monotherapy with ICS is not recommended [4]

Results

Discussion

Conclusion